Table 5 Studies evaluating NETs biomarkers in COVID-19 associated thromboembolism
From: Clinical significance of neutrophil extracellular traps biomarkers in thrombosis
First author/year | Study design | Included patients | Groups (No. patients) | Samples processing | NETs biomarkers | Analytical methods for NETs biomarkers | Detailed values |
|---|---|---|---|---|---|---|---|
Ouwendijk et al (2021) [108] | Case–control and cohort | Critically ill patients with COVID-19 | Thrombosis (n = 44) vs. No thrombosis (n = 33) vs. HC (n = 7) | Plasma | MPO-DNA | ELISA | NA |
Petito et al (2021) [105] | Case–control and cohort | Hospitalized patients with COVID-19 | VTE (n = 8) vs. No VTE (n = 27) vs. HC (n = 31) | Plasma, 4000 × g, 10 min | H3Cit | ELISA | NA |
MPO-DNA | ELISA | NA | |||||
Zuo et al (2021) [107] | Case–control | Hospitalized patients with COVID-19 and thrombosis | Thrombosis (n = 11) vs. No thrombosis (n = 33) | Serum | Calprotectin | ELISA | NA |
MPO-DNA | ELISA | NA | |||||
H3Cit | ELISA | NA | |||||
DNA | PicoGreen fluorimetry | NA |